IL33 and osteoarthritis: Furthermore, decreased proteoglycan loss in human OA cartilage with IL-37 via inhibition of MMP-3 expression and the protection of stem cells in an inflammatory osteoarthritis-like microenvironment for cartilage formation support IL-33 and IL-37 as potential therapeutics [20,85,86,87].